Revvity RVTY
United StatesHealthcare · Diagnostics & ResearchUSD
135.87 USD (−11.5%)
15 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Revvity, Inc. is a life sciences and diagnostics company that provides instruments, reagents, and services for laboratories, pharmaceutical research, and clinical diagnostics, generating recurring revenue from consumables and services.
Key points
from its scores- ✓Good share-price trend8.5
- ✕Little or no dividend3.3
- ✕Demanding valuation3.8
- ✕Weak growth4.6
AI analysis
bottom line, main risk, context and newsThe strong recent appreciation and positive momentum contrast with weak growth and profitability fundamentals; wait for improved execution or a more attractive valuation before adding.
Revvity shows acceptable financial health (score 6.36) with moderate debt (Net Debt/EBITDA 2.65) and good liquidity (1.80), but its quality is weak (ROE 3.21, ROIC 4.70) and its valuation is demanding (P/E 73.49, though forward P/E of 26.06 and PEG of 0.73 moderate the concern). Growth is low (revenue +1.30%) and the dividend is nominal (0.18%), but momentum is strong (41.18% over 12 months).
The main risk is the demanding valuation (P/E 73.49) in a context of low organic growth (revenue +1.30%), leaving little room for error if momentum reverses or if the rising long-term rate environment compresses multiples.
Context and risks
No recent relevant news and no material exposure to current macro factors: the company operates in diagnostics and life sciences, with moderate debt (Net Debt/EBITDA 2.65) and no dependence on commodities or critical shipping routes. The rise in long-term U.S. rates could slightly affect its valuation due to duration, but its forward P/E of 26 and stable cash generation limit the impact.
Is Revvity stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 114% above the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 73.5 | 26.7 | +175% |
| EV / EBITDA | 22.2 | 14.5 | +54% |
| Price / book | 2.4 | 4.1 | −42% |
| Price / sales | 5.9 | 3.4 | +72% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 3.8 out of 10 (median for Healthcare: 4.7).
Average analyst target: 135.87 USD, −11.5% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 4.8 (sector 5.5), Growth 4.6 (sector 6.6).
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 73.5
- Forward P/E
- 26.1
- EV / EBITDA
- 22.2
- Price / book
- 2.4
- Price / sales
- 5.9
- PEG
- 0.73
- Market cap
- 17.1B USD
- Enterprise value
- 19.5B USD
Profitability
- ROE
- 3.2%
- ROA
- 2.4%
- ROIC (approx.)
- 4.7%
- Gross margin
- 55.0%
- Operating margin
- 17.1%
- Net margin
- 8.2%
- Free cash flow
- 605.0M USD
- FCF yield
- 3.5%
- Cash conversion
- 69%
Solvency
- Total debt
- 3.3B USD
- Net debt
- 2.3B USD
- Cash
- 1.0B USD
- EBITDA
- 875.8M USD
- Net debt / EBITDA
- 2.65
- Debt / equity
- 46.23
- Current ratio
- 1.80
- Quick ratio
- 1.36
Growth
- Revenue growth
- +1.3%
- Earnings growth
- +1.2%
- EPS (TTM)
- 2.09 USD
- EPS (forward)
- 5.89 USD
Dividend
- Dividend yield
- 0.2%
- Payout
- 13.4%
Risk and market
- Beta
- 1.06
- Analyst consensus
- Buy (15)
- Target price
- 135.87 USD
- 52-week range
- 81.22 – 166.25
Recent news
All RVTY news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Revvity
Is Revvity stock cheap or expensive?
On P/E and EV / EBITDA, it trades 114% above the Healthcare median on average. Valuation score: 3.8 out of 10 (median for Healthcare: 4.7). Average analyst target: 135.87 USD, −11.5% versus the price. This is not investment advice.
What score does Revvity get on MeridIAn Screener?
It scores 5.1 out of 10, rank 1,667 of 2,130 (better than 21% of the companies analysed). Its strongest category is Momentum (8.5) and its weakest, Dividend (3.3). Analysis of 08/10/2026.
What is Revvity's P/E ratio?
Its P/E is 73.5: the share price equals 73.5 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 26.1.
How much is Revvity worth on the stock market?
Its market capitalisation is 17.1B USD and its enterprise value, debt included, is 19.5B USD.
How much debt does Revvity have?
Its net debt (debt minus cash) is 2.3B USD. That is 2.65 times its EBITDA; the Healthcare median is 1.53.
Does Revvity pay a dividend?
Yes: its dividend yield is 0.18% and it pays out 13% of its earnings.
How has Revvity stock performed over the last year?
It has risen 74.4% over the last year, excluding dividends. Over the last 52 weeks it has traded between 81.22 and 166.25 USD. Past performance does not guarantee future results.
What do analysts think of Revvity?
15 analysts cover it; their average recommendation is “Buy” and their average target is 135.87 USD (−11.5% versus the price). It is an estimate, not market data.